Sun Pharmaceutical Industries has announced plans to acquire U.S.-listed Organon & Co. in a deal valued at nearly $12 billion, marking one of the largest overseas acquisitions by an Indian pharmaceutical firm. The transaction signals a major push by Sun Pharma to expand its global footprint and diversify its product portfolio.
The all-cash deal values Organon at roughly $14 per share and includes the assumption of debt, bringing the total enterprise value close to $12 billion. The acquisition is expected to close following regulatory approvals and customary conditions. It reflects a significant premium over Organon’s recent trading levels, underscoring Sun Pharma’s strategic intent.
READ: Pharma giants move to sell medicines directly to patients (November 8, 2025)
Sun Pharma, India’s largest drugmaker, has built a strong presence in generics and specialty medicines across global markets. Organon, spun off from Merck in 2021, focuses on women’s health, biosimilars, and a portfolio of established medicines. By combining these strengths, Sun Pharma aims to deepen its presence in high-growth therapeutic areas while gaining access to Organon’s established global distribution network.
The acquisition holds strategic importance as it allows Sun Pharma to scale up in women’s health and biosimilars, segments that experience rising demand worldwide. Organon’s portfolio spans more than 100 markets, giving Sun Pharma immediate access to a broader customer base and diversified revenue streams. This move positions the Indian firm to compete more aggressively with global pharmaceutical leaders.
To fund the deal, Sun Pharma plans to use a mix of internal cash reserves and external financing, including bridge loans arranged through international banks. This balanced financing approach is designed to maintain liquidity while supporting long-term growth objectives. Analysts expect the transaction to enhance earnings over time, though near-term debt management will remain a key focus.
READ: Pharma air routes disrupted due to Middle East war, risking cancer drug supply (March 16, 2026)
Market reaction has been cautiously optimistic, with investors viewing the acquisition as a bold step toward global expansion. The deal could significantly boost Su n Pharma’s revenue and profitability once integration is complete. However, execution risks and regulatory hurdles remain important considerations.
Looking ahead, the success of the acquisition will depend on effective integration and the ability to unlock synergies across every company. If executed well, the deal could redefine Sun Pharma’s global standing and mark a new phase in the international expansion of Indian pharmaceutical companies.